THANK YOU FOR SUBSCRIBING
Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Healthcare Tech Outlook
Professor Tomasz Banasiewicz, M.D., PhD, WarmieWARMIE is not a simple thermometer and is capable of not only single-point temperature measurements but also evaluating patterns of temperature changes. Given that body temperature changes throughout the day and depends on multiple conditions, it is more accurate to assess many measurements throughout the day and analyse them in comparison to an individual patient's baseline.
To this end, Warmie offers a personalised medicine approach and based on time-series pattern recognition, alerts the owner of potential health risks. The utility of this innovative solution is not restricted to measuring body temperature during viral infections. It can also be used in constant monitoring of unconscious patients treated in intensive medical wards, as well as patients who suffer from chronic wounds (such as diabetic foot ulcers). This increases the safety of these patients by rapid notification (of patients or caring persons, including medical personnel) in case of temperature deviation. Due to its ease of use, constant telemedical monitoring, automatic evaluation of temperature changes, and personalised suggestions, WARMIE is a highly sought after solution in the market.
The team at Warmie consists of scientists with a strong background in surgery, dermatology, and data analysis. As such, the solutions proposed by the team are heavily backed up by scientific research. "We saw a prominent gap in medical diagnostics. Temperature measurement is one of the essential objective parameters that are easy to get, but not used to the full extent of its possibilities. We wanted to change that. Along the way, we realised that this solution not only makes sense for scientific purposes but could be useful for the general public. We decided to turn it into a product," says Banasiewicz. Warmie's team is diverse and already has experience in working with Medigent Foundation, where the team members showed their skills in conducting clinical studies, scientific publishing, and made software for clinical decision assistance for doctors. Coming from the Medigent Foundation, the team is well prepared to enter the medical device market.
With its unique capabilities, Warmie has positioned itself a notch above other solutions in the market and is planning to expand rather quickly. For Warmie, the most important step right now is a clinical study to confirm its usefulness in decreasing the cost of healthcare and increasing safety for the patients in multiple medical indications. The company is planning to conduct a trial for continuous temperature monitoring of wounds after surgery, rapidly indicating potential side effects like surgical site infections. This way, WARMIE could be used to quickly initiate antibiotic therapy in such cases and protect patients from more severe side effects.
Company
Warmie
Management
Professor Tomasz Banasiewicz, M.D., PhD, Warmie
Description
Warmie monitors body temperature constantly and prescreens people at risk who should seek medical help at the initial stage of the viral infection. WARMIE is not a simple thermometer and is capable of not only single-point temperature measurements but also evaluating patterns of temperature changes. Given that body temperature changes throughout the day and depends on multiple conditions, it is more accurate to assess many measurements throughout the day and analyse them in comparison to an individual patient's baseline. To this end, Warmie offers a personalised medicine approach and based on time-series pattern recognition, alerts the owner of potential health risks
Warmie News
The companies WARMIE and Polmedi are joining forces to launch a joint international initiative. They also have plans to secure up to 2 million euros from the market for further development.
The merger results from the desire to achieve synergy by combining the complementary competencies of both companies in the medical market. Discussions about collaboration were initiated in 2021 by Professor Tomasz Banasiewicz, the patron and active co-founder of both firms. The merger aligns with the maturation of the iWound system's business and process.
WARMIE is a recognized brand in the domestic market, awarded in competitions such as the "Orzeł Innowacji" by Rzeczpospolita and the "Polska Nagroda Innowacyjności 2022." They specialize in the production and certification of medical equipment, including the WARMIE temperature sensor. Polmedi's flagship product is the iWound telemedical system, available as a mobile and web application, designed for treating chronic wounds, postoperative wounds, and diabetic foot syndrome.
The merger facilitates the integration of both companies' software into a unified system, benefiting existing and future users. Polmedi leverages WARMIE's expertise in medical product certification, creating a shared industry contact base for expanding the customer base. The merger also results from discussions with international investors interested in investing in a comprehensive solution encompassing medical hardware (WARMIE) and telemedical systems (iWound).
The companies are conducting research and development to introduce an innovative device for negative pressure wound therapy. Each product is at a different stage of development, providing potential investors with a stable and consistent development plan for the coming years.
The merger also enables participation in tenders and requests for proposals that were previously inaccessible to individual entities. The expanded product offering allows reaching a broader patient audience, and the new system opens up communication channels that were not utilized before.
New products and services have been translated into multiple languages for foreign markets, with a strategic focus on establishing a presence in the Czech Republic, Slovakia, Lithuania, Latvia, Estonia, and the United Kingdom. The initial implementations are scheduled for the first quarter of 2024, considering differences in healthcare structures and legislative processes in these countries.
Short-term plans involve introducing an upgraded version of the application, tested over the past months. There are also intentions to expand the scope of therapies within the application, with a focus on diabetic foot therapy and postpartum wounds. The long-term goal is to make the iWound application an integral part of the wound healing process in Poland and establish it as a standard in every hospital nationwide.